

Fig. 2. Effects of PEG-Hb, SNO-PEG-Hb or solvent on CBF (coronary blood flow) and CVR (coronary vascular resistance) in ischemic myocardium. LF-5=at 5 min of low flow, D-5, 10, 15 and 20=at 5, 10, 15 and 20 min after the onset of PEG-Hb, SNO-PEG-Hb or solvent infusion, Off-10 and Off-20=at 10 and 20 min after withdrawal of PEG-Hb, SNO-PEG-Hb or solvent infusion, respectively. Data are mean±SEM. * p <0.05, ** p <0.01 vs. the control group.

Fig. 2 shows that SNO-PEG-Hb increased CBF (p <0.05) and decreased CVR (p <0.05) in ischemic hearts, while PEG-Hb decreased CBF (p <0.01) and increased CVR (p <0.01). The solvent for PEG-Hb or SNO-PEG-Hb did not alter either CBF or CVR. Fig. 3 shows that FS decreased after the onset of coronary hypoperfusion, while FS increased along with either SNO-PEG-Hb (p <0.01) or PEG-Hb (p <0.05) infusion. Fig. 4 shows that LER decreased after the onset of coronary hypoperfusion, while increasing along with either SNO-PEG-Hb or PEG-Hb infusion (both p <0.01). Fig. 5 shows myocardial oxygen consumption decreased after the onset of coronary hypoperfusion, while it increased along with the SNO-PEG-Hb infusion (p <0.05) and decreased along with the PEG-




Fig. 3. Effects of PEG-Hb, SNO-PEG-Hb or solvent on FS (fractional shortening) in ischemic myocardium. Abbreviations are same as in Fig. 1. Data are mean±SEM. * p <0.05, ** p <0.01 vs. the control group.

Hb infusion (p <0.05). The infusion of the solvent for PEG-Hb or SNO-PEG-Hb changed none of these parameters during coronary hypoperfusion. These results indicate that PEG-Hb that transfer oxygen to the myocardium with limited flow primarily decreases the severity of myocardial ischemia even with decreases in CBF, and SNO-PEG-Hb that transfers oxygen and release NO further increased CBF and ameliorated the severity of myocardial ischemia.

Fig. 6 shows the effect of nitroglycerin on the SNO-PEG-Hb-induced increase of CBF (Fig. 6A), FS (Fig. 6B) and LER




Fig. 4. Effects of PEG-Hb, SNO-PEG-Hb or solvent on LER (lactate extraction ratio) (B) in ischemic myocardium. Abbreviations are same as in Fig. 1. Data are mean±SEM. * p <0.05, ** p <0.01 vs. the control group.




Fig. 5. Effects of PEG-Hb, SNO-PEG-Hb or solvent on myocardial oxygen consumption in ischemic myocardium. Abbreviations are same as in Fig. 1. Data are mean \pm SEM. * p <0.05, ** p <0.01 vs. the control group.

(Fig. 6C). Treatment with nitroglycerin increased CBF, FS and LER, while SNO-PEG-Hb did not further increase CBF.

5. Discussion

In the present study, we demonstrated that SNO-PEG-Hb, a new type of Hb derivative with high molecular weight, increases CBF and improves contractile and metabolic dysfunction of ischemic hearts.

Hb is known to be a potent vasoconstrictor and an administration of native Hb resulted in a hypertensive reaction with previous reports [2,3]. Hb-induced vasoconstriction is explained by the fact that Hb is a potent scavenger of NO in the vessels and causes vasoconstriction. This vasoconstrictive property should be attenuated for the use as a tool for oxygen therapeutics because vasoconstriction itself decreases the transport of oxygen to the ischemic tissues. First, the molecular size of Hb derivatives is important. Native Hb, having a molecular weight of 56 kDa, easily extravasates into the endothelium and scavenge NO inside of the vessel walls [24]. Increasing of the molecular size of Hb may prevent this extravasation and then avoid the vasoconstriction. Indeed, our previous reports demonstrated that the pegylation of native Hb decreased the endothelium permeability [24] and attenuated Hb-induced hypertension to some extent [8,9]. Next, the cysteine residue of Hb is recently proposed to be covalently bound with NO and this S-nitrosylated Hb retains NO-like bioactivity [5,6]. In the circulation, native Hb undergoes S-nitrosylation, which may regulate blood flow [6]. Although the physiological roles and the amount of these molecules in the circulation still remain controversial, the preparation of artificial SNO-Hb is possible. In our previous reports, SNO-Hb had a decreased vasoconstrictive activity in rat circulation after a bolus infusion [8], suggesting S-nitrosylation of Hb molecules is a promising method to




Fig. 6. Effects of SNO-PEG-Hb on CBF (A), FS (B) and LER (C) in the presence of nitroglycerin in ischemic myocardium. Abbreviations are same as in Fig. 1. Data are mean \pm SEM.

control the vasoconstrictive activity of native Hb for the use for oxygen therapeutics. We finally pegylated SNO-Hb to prevent extravasation and to prolong the circulatory retention. We examined whether *S*-nitrosylation of PEG-Hb may contribute to an increase in CBF and exerts cardioprotective effects in ischemic canine heart.

In the present study, PEG-Hb decreased CBF to some extent, supporting the idea that Hb still has some vasoconstrictive activity. Although this PEG-Hb-induced vasoconstrictive property was not predicted by the findings based on rat experiments, there are several explanations. First, in the non-ischemic condition, since the level of produced NO is not high, PEG-Hb-induced NO scavenging effects may not contribute to vasoconstriction. However, when NO is produced more in the ischemic hearts than the non-ischemic hearts, the NO scavenging effects of PEG-Hb are augmented and attenuate CBF. Second, in the ischemic condition, the endothelium permeability was increased [25] and then even PEG-Hb might extravasate to some extent. Third, the strain difference between the canine that was used in the present study and rats that were used in the previous studies. Although PEG-Hb decreased CBF, even if so, it is intriguing to observe that the severity of myocardial ischemia is attenuated; this is because PEG-Hb directly transports oxygen to the ischemic myocardium with anaerobic metabolism. The oxygen transporting capacity of PEG-Hb is reported in the rat hemorrhagic shock model [26].

In contrast to Hb, SNO-Hb did not increase systemic blood pressure, suggesting that NO released from SNO-Hb may have compensated for the NO scavenging by the heme in SNO-Hb [5,6]. The present study also showed that SNO-PEG-Hb further increased CBF and further improved contractile and metabolic dysfunction in ischemic canine heart without systemic hypertensive reaction. The fact that SNO-PEG-Hb decreased CVR may suggest that NO released from SNO-PEG-Hb in ischemic heart and can overcome the coronary vasoconstriction of PEG-Hb. To make this point clearer, we added an experiment to examine whether SNO-PEG-Hb still hold NO dilator activity in the presence of nitroglycerin. Treatment with nitroglycerin increased CBF, while SNO-PEG-Hb did not further increase CBF. Although we have no concrete data whether SNO-PEG-Hb holds oxygen-coupled allosteric release of NO, these results clearly indicate that SNO-PEG-Hb increase CBF as an NO donor. This line of evidence supports the idea that SNO-PEG-Hb is ideal to protect hearts against ischemic injury by direct and coronary flow-mediated oxygen supply.

Interestingly, the coronary hemodynamic and metabolic parameters did not completely return to the baseline level within 20 min after the withdrawal of the SNO-PEG-Hb infusion during coronary hypoperfusion. The half-lives of Hb molecule and NO bound to SNO-PEG-Hb were 11.5 h for Hb and 2.4 h for NO, respectively [9]. SNO-PEG-Hb may still have coronary vasodilating activity and oxygen transporting capacity, even if in the systemic circulation.

NO is believed to attenuate the severity of myocardial ischemia; NO increases CBF [11–13], decreases myocardial anaerobic metabolism [14], inhibits platelet aggregation [15,16] and leukocyte activation [17] and sympathetic nerve activity

[18] in ischemic hearts. Furthermore, NO is reported to mediate cardioprotection in the late phase of ischemic preconditioning, because 24 or 48 h after a brief period of ischemia, NO has an infarct size-limiting effect [27].

Taken together, even PEG-Hb attenuates the ischemic injury and despite decreased CBF, SNO-PEG-Hb may be a novel and ideal chemical to attenuate myocardial injury of ischemic heart disease.

Acknowledgments

The authors gratefully acknowledge the technical assistance of Akiko Ogai, Yoko Nagamachi, Tomi Fukushima and Junko Yamada for help with conduct of the experiments.

Supported by Grants-in-aid for the Japan Cardiovascular Research Foundation; Scientific Research (Nos. 12470153 and 12877107) from the Japanese Ministry of Education, Culture, Sports, Science and Technology; Human Genome, Tissue Engineering and Food Biotechnology (H13-Genome-011) in Health and Labor Sciences Research Grants Research, and Comprehensive Research on Aging and Health (H13-21seiki (seikatsu)-23) in Health and Labor Sciences Research Grants Research from Ministry of Health and Labor and Welfare, Japan.

References

- [1] Rioux F, Petitclerc E, Audet R, Drapeau G, Fielding RM, Marceau F. Recombinant human hemoglobin inhibits both constitutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings. *J Cardiovasc Pharmacol* 1994;24:229–37.
- [2] Keipert PE, Gonzales A, Gomez CL, MacDonald VW, Hess JR, Winslow RM. Acute changes in systemic blood pressure and urine output of conscious rats following exchange transfusion with diaspirin-crosslinked hemoglobin solution. *Transfusion* 1993;33:701–8.
- [3] Gulati A, Singh G, Rebello S, Sharma AC. Effect of diaspirin crosslinked and stroma-reduced hemoglobin on mean arterial pressure and endothelin-1 concentration in rats. *Life Sci* 1995;56:1433–42.
- [4] Olsen SB, Tang DB, Jackson MR, Gomez ER, Ayala B, Alving BM. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. *Circulation* 1996;93:327–32.
- [5] Jia L, Bonaventura C, Stamler JS. *S*-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. *Nature* 1996;380:221–6.
- [6] Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, et al. Blood flow regulation by *S*-nitrosohemoglobin in the physiological oxygen gradient. *Science* 1997;276:2034–7.
- [7] Pawloski JR, Swaminathan RV, Stamler JS. Cell-free and erythrocytic *S*-nitrosohemoglobin inhibits human platelet aggregation. *Circulation* 1998;97:263–7.
- [8] Nakai K, Togashi H, Yasukochi T, Sakuma I, Fujii S, Yoshioka M, et al. Preparation and characterization of SNO-PEG-hemoglobin as a candidate for oxygen transporting material. *Int J Artif Organs* 2001;24:322–8.
- [9] Nakai K, Sakuma I, Togashi H, Yoshioka M, Sugawara T, Satoh H, et al. *S*-nitrosylated polyethylene glycol-conjugated hemoglobin derivative as a candidate material for oxygen therapeutics. *Adv Exp Med Biol* 2003;519: 207–216 [Review].
- [10] Moncada S. Nitric oxide in the vasculature: physiology and pathophysiology. *Ann N Y Acad Sci* 1997;811:60–7.
- [11] Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980;288:373–6.
- [12] Johns RA, Peach MJ, Linden J, Tichotsky A. NG-monomethyl L-arginine inhibits endothelium-derived relaxing factor-stimulated cyclic GMP accumulation in cocultures of endothelial and vascular smooth muscle

- cells by an action specific to the endothelial cell. *Circ Res* 1990; 67:979–85.
- [13] Yamabe H, Okumura K, Ishizaka H, Tsuchiya T, Yasue H. Role of endothelium-derived nitric oxide in myocardial reactive hyperemia. *Am J Physiol* 1992;263:H8–H14.
- [14] Nakano A, Liu GS, Heusch G, Downey JM, Cohen MV. Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. *J Mol Cell Cardiol* 2000;32:1159–67.
- [15] Mollace V, Salvemini D, Anggard E, Vane J. Nitric oxide from vascular smooth muscle cells: regulation of platelet reactivity and smooth muscle cell guanylate cyclase. *Br J Pharmacol* 1991;104:633–8.
- [16] Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. *Proc Natl Acad Sci U S A* 1988;85:2800–4.
- [17] Wright CD, Mulsch A, Busse R, Osswald H. Generation of nitric oxide by human neutrophils. *Biochem Biophys Res Commun* 1989;160:813–9.
- [18] Cohen RA, Weisbrod RM. Endothelium inhibits norepinephrine release from adrenergic nerves of rabbit carotid artery. *Am J Physiol* 1988;254:H871–8.
- [19] Chin SY, Wang CT, Majid DS, Navar LG. Renoprotective effects of nitric oxide in angiotensin II-induced hypertension in the rat. *Am J Physiol* 1998;274:F876–82.
- [20] Nakai K, Matsuda N, Ohta T, Amano M, Takahashi TA, Sakuma I, et al. Lysophosphatidylcholine, a component of stromal phospholipids, as a candidate vasoconstrictive factor in stroma-free hemoglobin. *Artif Organs* 1994;18:198–205.
- [21] Akaike T, Inoue K, Okamoto T, Nishino H, Otagiri M, Fujii S, et al. Nanomolar quantification and identification of various nitrosothiols by high performance liquid chromatography coupled with flow reactors of metals and Griess reagent. *J Biochem* 1997;122:459–66.
- [22] Kitakaze M, Minamino T, Node K, Komamura K, Shinozaki Y, Mori H, et al. Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. *Circulation* 1995;92:950–61.
- [23] Abel FL. Maximal negative dP/dt as an indicator of end of systole. *Am J Physiol* 1981;240:H676–9.
- [24] Nakai K, Ohta T, Sakuma I, Akama K, Kobayashi Y, Tokuyama S, et al. Inhibition of endothelium-dependent relaxation by hemoglobin in rabbit aortic strips: comparison between acellular hemoglobin derivatives and cellular hemoglobins. *J Cardiovasc Pharmacol* 1996;28:115–23.
- [25] Horwitz LD, Kaufman D, Keller MW, Kong Y. Time course of coronary endothelial healing after injury due to ischemia and reperfusion. *Circulation* 1994;90:2439–47.
- [26] Hoshi Y, Hazeki O, Kakihana Y, Tamura M. Redox behavior of cytochrome oxidase in the rat brain measured by near-infrared spectroscopy. *J Appl Physiol* 1997;83:1842–8.
- [27] Qiu Y, Rizvi A, Tang XL, Manchikalapudi S, Takano H, Jadoon AK, et al. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. *Am J Physiol* 1997;273:H2931–6.



Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials

Masafumi Kitakaze, Masanori Asakura, Jiyoong Kim, Yasunori Shintani, Hiroshi Asanuma, Toshimitsu Hamasaki, Osamu Seguchi, Masafumi Myoishi, Tetsuo Minamino, Takahiro Ohara, Yoshiyuki Nagai, Shinsuke Nanto, Kouki Watanabe, Shigeru Fukuzawa, Atsushi Hirayama, Natsuki Nakamura, Kazuo Kimura, Kenshi Fujii, Masaharu Ishihara, Yoshihiko Saito, Hitonobu Tomoike, Soichiro Kitamura, and the J-WIND investigators*

Summary

Background Patients who have acute myocardial infarction remain at major risk of cardiovascular events. We aimed to assess the effects of either human atrial natriuretic peptide or nicorandil on infarct size and cardiovascular outcome.

Methods We enrolled 1216 patients who had acute myocardial infarction and were undergoing reperfusion treatment in two prospective, single-blind trials at 65 hospitals in Japan. We randomly assigned 277 patients to receive intravenous atrial natriuretic peptide (0.025 µg/kg per min for 3 days) and 292 the same dose of placebo. 276 patients were assigned to receive intravenous nicorandil (0.067 mg/kg as a bolus, followed by 1.67 µg/kg per min as a 24-h continuous infusion), and 269 the same dose of placebo. Median follow-up was 2.7 (IQR 1.5–3.6) years for patients in the atrial natriuretic peptide trial and 2.5 (1.5–3.7) years for those in the nicorandil trial. Primary endpoints were infarct size (estimated from creatine kinase) and left ventricular ejection fraction (gauged by angiography of the left ventricle).

Findings 43 patients withdrew consent after randomisation, and 59 did not have acute myocardial infarction. We did not assess infarct size in 50 patients for whom we had fewer than six samples of blood. We did not have angiographs of left ventricles in 383 patients. Total creatine kinase was 66459.9 IU/mL per h in patients given atrial natriuretic peptide, compared with 77878.9 IU/mL per h in controls, with a ratio of 0.85 between these groups (95% CI 0.75–0.97, $p=0.016$), which indicated a reduction of 14.7% in infarct size (95% CI 3.0–24.9%). The left ventricular ejection fraction at 6–12 months increased in the atrial natriuretic peptide group (ratio 1.05, 95% CI 1.01–1.10, $p=0.024$). Total activity of creatine kinase did not differ between patients given nicorandil (70520.5 IU/mL per h) and controls (70852.7 IU/mL per h) (ratio 0.995, 95% CI 0.878–1.138, $p=0.94$). Intravenous nicorandil did not affect the size of the left ventricular ejection fraction, although oral administration of nicorandil during follow-up increased the left ventricular ejection fraction between the chronic and acute phases. 29 patients in the atrial natriuretic peptide group had severe hypotension, compared with one in the corresponding placebo group.

Interpretation Patients with acute myocardial infarction who were given atrial natriuretic peptide had lower infarct size, fewer reperfusion injuries, and better outcomes than controls. We believe that atrial natriuretic peptide could be a safe and effective adjunctive treatment in patients with acute myocardial infarction who receive percutaneous coronary intervention.

Introduction

Despite availability of effective medical treatments, chronic heart failure remains a major cause of morbidity and mortality worldwide.^{1–3} Ischaemic heart disease, in turn, is one of the main causes of chronic heart failure.⁴ The most important treatment objectives are prevention of acute myocardial infarction, and, in individuals who have an acute myocardial infarction, reduction in infarct size and ischaemia or reperfusion injury.⁵ Only a few medications have been shown to decrease ischaemia or reperfusion injury.^{6–8}

Reperfusion of ischaemic myocardium reduces infarct size and improves left ventricular function, both of which contribute to better clinical outcomes in patients with acute myocardial infarction.^{9–11} However, reperfusion can also cause tissue damage.¹² Several

drugs have been trialled for the prevention or amelioration of such injuries, but results have not been consistently satisfactory.^{13–25} Recently, human atrial natriuretic peptide and nicorandil have both been shown to be effective for reduction of myocardial damage after acute myocardial infarction in basic and clinical studies.^{16–25} Atrial natriuretic peptide is a candidate for adjunctive treatment after acute myocardial infarction, because it has been shown to suppress the renin–angiotensin–aldosterone system and endothelin-1, both of which modulate infarct size and cardiac remodelling.¹⁹ Nicorandil is a combined adenosine triphosphate (ATP)-sensitive potassium channel opener and nitrate preparation that has also shown promise as an adjunctive treatment for acute myocardial infarction. In the clinical setting, however,

Lancet 2007; 370: 1483–93

See Comment page 1461

*Other investigators listed at end of study

Cardiovascular Division of Medicine, National Cardiovascular Centre, Suita, Osaka, Japan (Prof M Kitakaze MD, M Asakura MD, J Kim MD, O Seguchi MD, M Myoishi MD, T Ohara MD, Prof H Tomoike MD, Prof S Kitamura MD); Department of Clinical Research and Development, National Cardiovascular Centre, Suita, Osaka, Japan (M Kitakaze MD, M Asakura MD); Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan (Y Shintani MD, T Minamino MD); Research Institute, National Cardiovascular Centre, Suita, Osaka, Japan (H Asanuma MD); Department of Biomedical Statistics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan (T Hamasaki PhD); Heart Centre Department of Cardiology, Rinku General Medical Centre, Izumisano, Osaka, Japan (Y Nagai MD); Cardiovascular Division, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan (Prof S Nanto MD); Department of Cardiology, Uwajima-City Hospital, Uwajima, Ehime, Japan (K Watanabe MD); Division of Cardiology, Funabashi Municipal Medical Centre, Funabashi, Chiba, Japan (S Fukuzawa MD); Cardiovascular Division, Osaka Police Hospital, Osaka, Osaka, Japan (Prof A Hirayama MD); Department of Cardiology, Shinbeppu Hospital, Beppu, Oita, Japan (N Nakamura MD); Division of Cardiology, Yokohama City University Medical Centre, Yokohama,

Kanagawa, Japan (Prof K Kimura MD); Division of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Osaka, Japan (K Fujii MD); Department of Cardiology, Hiroshima City Hospital, Hiroshima, Hiroshima, Japan (M Ishihara MD); and First Department of Medicine, Nara Medical University, Kashihara, Nara, Japan (Prof Y Saito MD)

Correspondence to: Professor Masafumi Kitakaze, Cardiovascular Division of Medicine, National Cardiovascular Centre Suita, Osaka 565-8565, Japan
kitakaze@hsp.ncvc.go.jp

the beneficial effects of atrial natriuretic peptide and nicorandil have only been tested in single-centre studies with small sample sizes.²⁰⁻²⁵ The Japan working group studies on acute myocardial infarction for the reduction of necrotic damage by human atrial natriuretic peptide or nicorandil (J-WIND-ANP and J-WIND-KATP, respectively) aimed to assess the value of these drugs as adjuncts to percutaneous coronary intervention for patients with acute myocardial infarction.

Methods

Patients

We have described the protocols for the two trials previously.^{26,27} In brief, we recruited patients to two independent, investigator-initiated, investigator-led, multicentre, prospective, randomised, single-blind, controlled trials at 65 hospitals. 27 hospitals participated in the atrial natriuretic peptide trial, and 38 separate hospitals in the nicorandil trial (table 1); the two studies were completely independent. We initially planned to include fewer hospitals, but we increased the number to promote enrolment of sufficient patients.

Eligibility criteria were age between 20 and 79 years; chest pain for more than 30 min; at least 0.1 mV of ST segment elevation in two adjacent ECG leads; admission to hospital within 12 h of the onset of symptoms; and one instance of acute myocardial infarction. Exclusion criteria were a history of myocardial infarction; left main trunk stenosis; severe liver or kidney dysfunction or both; suspected aortic dissection; previous coronary artery bypass grafting; and a history of drug allergy.

All patients gave written informed consent immediately after admission to hospital, and were asked to sign the same consent form again after 2 weeks when they had more time to decide. This system was applied on the recommendation of the institutional review boards. Only one patient, who was in the nicorandil group, withdrew their consent at their second opportunity. We enrolled patients from Oct 24, 2001, to Dec 13, 2005. The study protocol was approved by the institutional review boards and ethics committees of all participating hospitals, and was in accordance with the Declaration of Helsinki.

Procedures

An independent statistician generated our randomisation lists with a computer, by the permuted-block method. Within each centre, the block length was eight. Treatment allocations were concealed in opaque sealed envelopes until patients were enrolled. Physicians were not aware of the random assignments of patients until the follow-up stage; patients and those who analysed the data were unaware of the treatment assignment for the duration of the study. Both trials were designed as single-blind studies.

277 patients who were enrolled in the atrial natriuretic peptide trial were randomly assigned to receive an intra-

venous infusion of this drug after reperfusion treatment, at 0.025 µg/kg per min for 3 days, and 292 a placebo of 5% glucose solution by the same method. 276 patients in the other trial were randomly assigned to intravenous nicorandil, infused at 1.67 µg/kg per min for 24 h after bolus injection of nicorandil at a dose of 0.067 mg/kg, and 269 were assigned to 0.9% saline solution, by the same method. Previous studies have shown substantial cardiovascular protection with atrial natriuretic peptide and nicorandil at these doses.^{20,22} Of the 276 patients assigned to receive nicorandil, 61 were given nicorandil orally, at the discretion of individual investigators, during the follow-up period.

We planned to stop the administration of treatment drugs in case of severe hypotension, which was defined as systolic blood pressure of less than 90 mm Hg, because of the vasodilator effect of these drugs. The study protocol did not restrict or specify any other diagnostic or therapeutic methods in the acute phase (2–8 weeks after acute myocardial infarction) or chronic phase (6–12 months).

We obtained data on baseline characteristics, emergent catheterisation, and medication at discharge after 1 month; data on follow-up catheterisation and medication after 6 months; and data on medication after 24 months. We also followed up all patients for cardiovascular events (ie, cardiac death, readmission to hospital due to heart failure, new onset of acute coronary syndrome, or revascularisation of new lesions) until the end of August, 2006. We took blood samples to measure concentrations of creatine kinase at a central laboratory, before the procedure and at 1, 3, 6, 9, 12, 18, 24, 36, 48, and 72 h after the onset of reperfusion.¹⁴ We analysed total creatine kinase for all patients with at least six blood samples. We obtained right anterior oblique views with angiography of the left ventricle once in the acute phase (2–8 weeks), and once in the chronic phase (6–12 months).

Our primary endpoints were infarct size (which was estimated as the area under the concentration versus time curve for creatine kinase)¹⁴ and ventricular ejection fraction (which was assessed by angiography of the left ventricle at 6–12 months after hospital admission).¹⁵ The prespecified secondary endpoints were survival rate; cardiovascular events (such as cardiac death, readmission to hospital for heart failure, new onset of acute coronary syndrome, or revascularisation of new lesions); incidence of cardiac death or readmission to hospital for

	J-WIND-ANP study	J-WIND-KATP study
1–4 patients	7 hospitals	9 hospitals
5–9 patients	3 hospitals	13 hospitals
10–19 patients	7 hospitals	6 hospitals
More than 20 patients	10 hospitals	10 hospitals

Table 1: Distribution of patients between participating hospitals




Figure 1: Trial profiles

ANP=atrial natriuretic peptide. AMI=acute myocardial infarction. *Fewer than six blood samples.

heart failure; or reperfusion injury before discharge from coronary care unit (such as malignant ventricular arrhythmia during reperfusion, recurrence of ST segment elevation, or worsening of chest pain). We also assessed infarct size, estimated by peak creatine kinase and troponin T;^{28,29} left ventricular ejection fraction at acute phase; and end-diastolic or end-systolic volume index (assessed by angiography of the left ventricle). We looked at the effects of each drug on the primary endpoints in prespecified subgroups (sex, age, body-mass index, pre-angina, elapsed time between acute

myocardial infarction and intervention, diabetes mellitus, hyperlipidaemia, smoking, and family history of acute myocardial infarction). We also did post-hoc analyses on the effect of chronic administration of nicorandil on the ejection fraction.

All data were collected by Koteisho-kyokai (Tokyo), an organisation established by the Japanese government in 2001–2003 and by NTT Data (Tokyo) in 2004–2006. Left ventricular ejection fraction and end-diastolic volume were measured by the area-length method, from angiography of the left ventricle. Two independent

interpreters, who were unaware of the treatment assigned to patients, measured left ventricular ejection fractions from the angiographs. We calculated the average value, unless the two investigators disagreed, in which case we referred to a third opinion.

Clinical findings and medications during the follow-up period were reported to a data and safety committee after registration. This committee, which consisted of three physicians and one statistician who did not participate in the trial, monitored all adverse events. Research nurses or doctors visited all participating hospitals to check that patients were registered, drugs were given, and data collected according to the protocol. Committee members did not provide any results to the steering committee, because discontinuation of the study was not recommended.

Statistical analysis

We calculated that a sample size of 300 patients would be needed in each group to detect a 20% reduction in the most important primary endpoint (total creatine kinase) with a statistical power of 80% at significance level of 0.05 (with a two-sided *t* test), accounting for dropout of some patients. We set equal sample sizes in both groups, because we expected to see almost the same reduction in infarct size with either treatment. Since creatine kinase and total creatine kinase are both log-normally distributed,³⁰ total creatine kinase was log-transformed before analysis. The left ventricular ejection fraction was also log-transformed before the analysis since the distribution was skewed.

Statistical analysis was done according to a prespecified analytical plan. Efficacy analysis was based on intention to treat. The primary efficacy analyses for total creatine kinase and left ventricular ejection fraction were done simply by *t* test. The estimated mean and differences on the log scale were transformed back to the original scale and were expressed as geometric means and ratios of geometric mean. If the calculated

95% CI for the ratio of the geometric mean did not cross the point of no effect (ie, 1) the difference between groups was regarded as significant. Furthermore, analysis of covariance for the two endpoints was used to estimate adjusted mean comparison, with effect of covariates and the interactions. We imputed missing data for patients by the predicted mean imputation method, with nonlinear regression. We applied multiple imputation techniques (with group means, Markov Chain Monte Carlo, Bayesian bootstrap, and last-observation-carried-forward methods) to assess the robustness and sensitivity of our conclusions.

Proportions were examined by Fisher's exact test. We examined time-to-event by the Kaplan-Meier method to estimate the survival for each group and then the differences in survival between groups by the log-rank test. The Cox proportional hazards model was used to assess baseline risk factors and an adjusted hazard ratio. The proportional hazards assumption was investigated graphically, with a test based on Schoenfeld residuals.^{31,32}

All tests were two-sided, and a *p* value of less than 0.05 was regarded as significant. All analyses were done with SAS software (version 8.2). The trials are registered with Clinicaltrials.gov, numbers NCT00212056 and NCT00212030.

Role of the funding source

The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data at the end of the study, and had final responsibility for the decision to submit for publication.

Results

Figure 1 shows the trial profile. Table 2 shows baseline characteristics. Median follow-up was 2.7 (IQR 1.5–3.6) years in the atrial natriuretic peptide trial and 2.5 (1.5–3.7) years in the nicorandil trial. Table 3 shows

	Atrial natriuretic peptide study			Nicorandil study		
	ANP (n=277)	Control (n=292)	<i>p</i>	Nicorandil (n=276)	Control (n=269)	<i>p</i>
Age (years)	63.0 (10.4)	61.8 (10.7)	0.1652	61.1 (11.4)	63.7 (10.2)	0.0035
Sex (male)	211 (76.2%)	243 (83.2%)	0.0374	246 (89.1%)	220 (81.8%)	0.0153
Body-mass index	24.3 (3.5)	24.0 (2.9)	0.3733	24.2 (3.0)	23.4 (2.8)	0.0007
Killip classification (I, II, III, IV)	88.6%, 9.5%, 1.1%, 0.8%	90.3%, 7.5%, 1.4%, 0.7%	0.5274	91.1%, 8.2%, 0.4%, 0.4%	92.0%, 4.2%, 2.7%, 1.1%	0.7843
Pre-angina	105 (44.5%)	118 (46.1%)	0.7862	111 (44.6%)	111 (43.9%)	0.9284
Risk factors						
Hypertension	137 (56.1%)	162 (62.1%)	0.2046	127 (48.5%)	137 (53.9%)	0.2190
Diabetes mellitus	81 (33.8%)	86 (33.9%)	1.0000	104 (39.5%)	82 (32.9%)	0.1413
Hyperlipidaemia	127 (54.3%)	131 (50.6%)	0.4181	121 (46.7%)	114 (46.2%)	0.9291
Smoking	158 (63.7%)	175 (67.3%)	0.4022	178 (68.7%)	170 (66.1%)	0.5732

Data are number (%) or mean (SD), unless otherwise specified. ANP=atrial natriuretic peptide.

Table 2: Baseline characteristics on admission

	Atrial natriuretic peptide study		Nicorandil study	
	ANP (n=277)	Control (n=292)	Nicorandil (n=276)	Control (n=269)
Elapsed time (h)*	4.00 (3.00–6.00)	4.00 (2.50–6.00)	3.50 (2.50–5.00)	3.50 (2.50–5.00)
Infusion time (h)	1.00 (0.50–1.00)	1.00 (0.50–1.00)	0.70 (0.50–1.00)	0.75 (0.50–1.00)
IRA (LAD, LCx, RCA)	55.3%, 6.4%, 38.3%	52.3, 10.6, 37.1%	53.9, 7.4, 38.7%	44.5, 9.9, 45.6%
Stents	176 (63.5%)	193 (66.1%)	187 (67.8%)	183 (68.0%)
Rescue	64 (23.1%)	92 (31.5%)	94 (34.1%)	92 (34.2%)
Intra-aortic balloon pump	17 (6.1%)	14 (4.8%)	14 (5.1%)	15 (5.6%)
Final stenosis (<75%)	246 (93.5%)	266 (94.7%)	257 (96.6%)	255 (97.0%)
Final thrombolysis in myocardial infarction (0, 1, 2, 3)	3.9%, 1.9%, 5.0%, 89.1%	5.2%, 0.7%, 4.1%, 90.0%	3.7%, 0.7%, 5.2%, 90.3%	3.4%, 1.1%, 6.9%, 88.5%
Medications at 1 month				
ACE inhibitor	155 (57.8%)	173 (60.7%)	164 (61.0%)	163 (62.0%)
ARB	77 (28.7%)	99 (34.7%)	72 (26.8%)	69 (26.2%)
Spironolactone	28 (10.4%)	33 (11.6%)	17 (6.3%)	22 (8.4%)
β blocker	112 (41.8%)	128 (44.9%)	110 (40.9%)	121 (46.0%)
Aspirin	225 (84.0%)	252 (88.4%)	251 (93.3%)	250 (95.1%)
Nitrates	81 (30.2%)	86 (30.2%)	50 (18.6%)	63 (24.0%)
Statins	129 (48.1%)	156 (54.7%)	126 (46.8%)	115 (43.7%)
Nicorandil	62 (23.1%)	52 (18.2%)	79 (29.4%)	34 (12.9%)
Medications at 6 months				
ACE inhibitor	103 (48.1%)	117 (44.8%)	120 (50.6%)	131 (53.9%)
ARB	69 (32.2%)	110 (42.1%)	68 (28.7%)	75 (30.9%)
Spironolactone	26 (12.1%)	26 (10.0%)	11 (4.6%)	15 (6.2%)
β blocker	93 (43.5%)	118 (45.2%)	104 (43.9%)	113 (46.5%)
Aspirin	179 (83.6%)	233 (89.3%)	217 (91.6%)	229 (94.2%)
Nitrates	51 (23.8%)	63 (24.1%)	37 (15.6%)	49 (20.2%)
Statins	112 (52.3%)	150 (57.5%)	123 (51.9%)	118 (48.6%)
Nicorandil	46 (21.5%)	39 (14.9%)	55 (23.2%)	23 (9.5%)
Medications at 24 months				
ACE inhibitor	66 (47.5%)	63 (37.5%)	83 (52.5%)	75 (49.3%)
ARB	42 (30.2%)	72 (42.9%)	39 (24.7%)	43 (28.3%)
Spironolactone	13 (9.4%)	21 (12.5%)	9 (5.7%)	4 (2.6%)
β blocker	57 (41.0%)	61 (36.3%)	77 (48.7%)	71 (46.7%)
Aspirin	113 (81.3%)	133 (79.2%)	143 (90.5%)	137 (90.1%)
Nitrates	29 (20.9%)	45 (26.8%)	23 (14.6%)	25 (16.4%)
Statins	66 (47.5%)	78 (46.4%)	81 (51.3%)	71 (46.7%)
Nicorandil	26 (18.7%)	26 (15.5%)	28 (17.7%)	11 (7.2%)

Data are median (IQR), number (%) or mean (SD), unless otherwise specified. ANP=atrial natriuretic peptide. IRA=infarct-related artery. LAD=left anterior descending coronary artery. LCx=left circumflex artery. RCA=right coronary artery. ARB=angiotensin receptor blocker. ACE=angiotensin-converting enzyme. *Period between acute myocardial infarction and start of intervention.

Table 3: Treatments and prescribed drugs

treatments and drugs throughout the study. Drugs used in the chronic stage did not differ between groups in either study, except that some patients in the nicorandil trial were given oral nicorandil during follow-up.

Table 4 and figure 2 show infarct size and left ventricular function at 2–8 weeks and 6–12 months in both studies. The ratio of total creatine kinase between the atrial natriuretic peptide and placebo groups was 0.85 (95% CI 0.75–0.97, $p=0.0155$); which indicates that atrial natriuretic peptide was associated with a reduction of 14.7% in infarct size. Subanalyses identified no factors that enhanced or reduced the

influence of atrial natriuretic peptide on infarct size (figure 2). Nicorandil did not reduce infarct size compared with placebo, and no factors affected this finding. Treatment with atrial natriuretic peptide tended to increase the left ventricular ejection fraction (ratio 1.043, 95% CI 1.000–1.089, $p=0.0525$) at 2–8 weeks after the onset of acute myocardial infarction, and at 6–12 months (ratio 1.051, 95% CI 1.006–1.099, $p=0.0236$). By contrast, table 4 and figure 2 show that left ventricular ejection fraction did not differ in patients given nicorandil and controls at either 2–8 weeks or 6–12 months.

	J-WIND-ANP study		p	J-WIND-KATP study		p
	Atrial natriuretic peptide	Control		Nicorandil	Control	
Infarct size						
n	255	280		269	260	
Creatine kinase (area under curve) (IU/L h)	66 459.9 (60 258.2-73 300.0)	77 878.9 (71 590.2-84 720.1)	0.016	70 520.5 (64 309.8-77 331.0)	70 852.7 (65 066.7-77 153.2)	0.941
Peak creatine kinase (IU/L)	2487.5 (2217.6-2790.3)	2784.2 (2526.7-3067.9)	0.141	2557.1 (2306.1-2835.4)	2428.7 (2199.8-2681.5)	0.479
Troponin-T concentration (12-18 h) (ng/mL)	5.36 (4.76-6.03)	6.13 (5.55-6.79)	0.084	6.18 (5.51-6.93)	5.60 (4.97-6.32)	0.244
Troponin T (96 h) (ng/mL)	2.57 (2.25-2.94)	2.94 (2.64-3.27)	0.125	2.63 (2.36-2.94)	2.89 (2.61-3.19)	0.225
Left ventricle (2-8 weeks)						
n	187	207		168	170	
Median elapsed time (days)*	18.5 (IQR 15.0-27.0)	19.0 (IQR 16.0-25.0)		17.0 (IQR 14.0-23.0)	17.0 (IQR 14.0-24.0)	
Ejection fraction	43.0% (41.8-44.3)	41.3% (40.0-42.6)	0.053	42.0% (40.7-43.3)	41.6% (40.4-42.9)	0.680
End diastolic volume index (mL/m ²)	98.8 (94.4-103.4)	102.3 (98.1-106.6)	0.272	111.2 (106.4-116.3)	105.9 (100.9-111.3)	0.147
End systolic volume index (mL/m ²)	54.2 (51.2-57.4)	58.3 (55.5-61.4)	0.058	62.8 (59.2-66.6)	60.4 (57.0-64.1)	0.360
Left ventricle (6-12 months)						
n	155	199		190	187	
Median elapsed time (days)*	196.5 (IQR 180.5-230.5)	200.5 (IQR 183.0-226.0)		195.0 (IQR 180.0-231.0)	195.5 (IQR 183.0-232.0)	
Ejection fraction	44.7% (43.4-46.0)	42.5% (41.2-43.9)	0.024	42.5% (41.2-43.8)	43.2% (42.0-44.4)	0.460
End diastolic volume index (mL/m ²)	100.6 (95.2-106.2)	100.9 (96.8-105.1)	0.930	109.8 (105.4-114.4)	105.7 (100.8-110.8)	0.230
End systolic volume index (mL/m ²)	54.2 (50.6-58.0)	56.0 (53.1-58.9)	0.452	61.7 (58.4-65.2)	58.5 (55.1-62.1)	0.198

Data are mean (95% CI) or median (IQR). *Time between acute myocardial infarction and start of intervention.

Table 4: Primary endpoints and other outcomes obtained by angiography of left ventricles

Figure 3 shows reperfusion injuries, survival rates, and cardiovascular events. Reperfusion injuries were less common in the atrial natriuretic peptide group than in the placebo group (ratio 0.743, 95% CI 0.58-0.952, $p=0.019$). Although there were no differences between groups in either survival rates or the incidence of cardiovascular events, both cardiac death and readmission to hospital for heart failure were lower in patients given atrial natriuretic peptide than in controls (HR 0.267, 95% CI 0.089-0.799, $p=0.0112$). By contrast, cardiac death and readmission to hospital for heart failure were not significantly lower in patients given nicorandil than in controls (HR 0.799, 95% CI 0.307-1.973, $p=0.5972$). When nicorandil was given orally throughout the study after reperfusion treatment, the change of left ventricular ejection fraction increased substantially between the acute and chronic phase. The ejection fraction was 3.66% in the 61 patients who were given nicorandil orally, and 1.47% in the 241 patients who were not (difference 2.20, 95% CI 0.17-4.22, $p=0.0338$).

In the atrial natriuretic peptide trial, 29 patients given that drug had severe hypotension during the acute phase, compared with one control. In the other trial, three patients in the nicorandil group had severe hypotension, compared with no controls. No other severe adverse events were reported during the course of either study.

Discussion

We showed that adjunctive, acute-phase treatment with atrial natriuretic peptide after reperfusion therapy in patients with acute myocardial infarction reduced infarct

size by 14.7%, increased the left ventricular ejection fraction during the chronic phase, and decreased the incidence of cardiac death and readmission to hospital because of heart failure. Intravenous treatment with nicorandil did not affect the primary endpoints, although patients who were given nicorandil orally had better cardiac function outcomes.

Interest in the cardioprotective effects of adenosine has increased, because of its variety of cardioprotective mechanisms. Unfortunately, in trials of adenosine, it only marginally improved infarct size and showed no clinical benefits.^{7,33} We hypothesised that treatment with atrial natriuretic peptide and nicorandil in the acute phase might prove more effective than chronic-phase treatment for limitation of infarct size. The first window of ischaemic preconditioning is mediated by opening of the KATP channel,³⁴ which is the mechanism of action of nicorandil; and the second window is mediated by nitric oxide and activation of G kinase, which is the mechanism of action of atrial natriuretic peptide.

Before this clinical trial, we had tested whether atrial natriuretic peptide could limit infarct size in a canine model in which the left anterior coronary artery was ligated for 90 min, followed by 6 h of reperfusion. Treatment with atrial natriuretic peptide reduced infarct size by about 40% after reperfusion (unpublished data). Our results are consistent with the finding of Hayashi and coworkers²⁰ that infusion of atrial natriuretic peptide immediately after reperfusion in patients with their first anterior acute myocardial infarction increased left ventricular ejection fraction.




Figure 2: Primary endpoints and subgroup analyses

CK=creatinine kinase. AMI=acute myocardial infarction. ANP=atrial natriuretic peptide. Panel A shows area under curve of creatine kinase concentration versus time. Panel B represents left ventricular ejection fraction measured at 6-12 months.




Figure 3: Secondary endpoints and other subanalyses
ANP=atrial natriuretic peptide.

The reduction of infarct size and the improvement of left ventricular ejection fraction might decrease mechanical stress on the non-infarcted myocardium, which might decrease hypertrophy and dilatation of the non-infarcted myocardium. Since cardiac hypertrophy and dilatation cause diastolic and systolic heart failure, a reduction of infarct size and an increase of left ventricular ejection fraction could mediate beneficial clinical outcomes. However, we need to do another large-scale clinical trial to target clinical outcomes such as cardiovascular death, because our primary aim here was to test the reduction of infarct size. Moreover, Hayashi and colleagues²⁰ showed that plasma concentrations of angiotensin II, aldosterone, and endothelin-1 were lower in patients given atrial natriuretic peptide than in controls. Sudden exposure to high concentrations of angiotensin II, aldosterone, and endothelin-1 for several days caused vascular or ventricular remodelling, and attenuation of these harmful effects by infusion of atrial natriuretic peptide could reduce the incidence of cardiac death and readmission to hospital for chronic heart failure.²⁰

One reason that nicorandil treatment did not limit infarct size in our study could be the size of the dose. Ishii and colleagues²⁵ have reported that one intravenous administration of a dose of nicorandil that was three times higher than that which we used decreased the infarct size and reduced the rate of cardiovascular death or readmission to hospital for chronic heart failure in 368 patients with acute myocardial infarction.

Patients in the nicorandil study who were given nicorandil orally in the chronic phase had greater increases in left ventricular ejection fraction, irrespective of whether nicorandil was given intravenously or orally. Since microvascular obstruction ten days after myocardial infarction was associated with left ventricular remodelling and poor prognosis, coronary perfusion might be improved by opening KATP channels in coronary blood vessels during the healing stage. The IONA study³⁵ showed that nicorandil could reduce the incidence of unstable angina in patients with stable angina.

Our finding that treatment with atrial natriuretic peptide in the acute phase reduced the incidence of readmission to hospital for chronic heart failure could help to reduce the physical, medical, and economic burdens on people around the world. Moreover, since intravenous nicorandil in the acute phase, followed by oral administration in the chronic phase, increased the left ventricular ejection fraction, chronic treatment with nicorandil could improve ventricular function for patients with myocardial infarction in the chronic phase.

Several limitations of our study should be discussed. First, physicians knew the random assignment of patients, and treatment for acute myocardial infarction in the chronic phase was not restricted accordingly; this

could have affected the difference in nicorandil treatment at the chronic phase. Second, although we planned to do angiography of the left ventricle when patients were admitted to hospital, some hospitals could not take angiographs, because of the additional medical cost. Therefore, baseline angiographs were absent for some patients. Third, the patterns of missing angiography data on left ventriculography differed between the two studies (which were done at different hospitals) and also between the atrial natriuretic peptide group and corresponding placebo group. We cannot explain this difference, but since we did not intervene in this procedure, we believe that it must be due to chance.

Contributors

Department of Cardiology, National Hospital Organisation Ehime National Hospital, Toon, Ehime, Japan (T Otani); Division of Cardiology, National Hospital Organisation Shizuoka Medical Centre, Sunto-Gun, Shizuoka, Japan (H Yokoyama); Department of Cardiology, Kameda Medical Centre, Kamogawa, Chiba, Japan (Y Hashimoto); Division of Cardiovascular disease of Medicine, Hokkaido Junkanki Hospital, Sapporo, Hokkaido, Japan (N Funayama); Department of Cardiology, Kyushu Kosei Nenkin Hospital, Kitakyushu, Fukuoka, Japan (H Yamamoto); Department of Cardiology, Surugadai Nihon University Hospital, Chiyoda-Ku, Tokyo, Japan (E Tachibana); Department of Cardiology, St Mary's Hospital, Kurume, Fukuoka, Japan (K Yamamoto); Department of Cardiology, Miki City Hospital, Miki, Hyogo, Japan (K Awano); Division of Cardiology, Cardiovascular Centre, Tsuchiya General Hospital, Hiroshima, Hiroshima, Japan (T Sakuma); Department of Cardiology, Himeji Brain and Heart Centre, Himeji, Hyogo, Japan (T Kajiya); Department of Cardiovascular Centre, National Hospital Organisation Kumamoto Medical Centre, Kumamoto, Kumamoto, Japan (K Fujimoto); Department of Cardiology, Fukuyama Cardiovascular Hospital, Fukuyama, Hiroshima, Japan (H Kohno); Division of Cardiology, Tokuyama Central Hospital, Shunan, Yamaguchi, Japan (T Iwami); Division of Cardiology, Mito Saiseikai General Hospital, Mito, Ibaraki, Japan (M Murata); Division of Cardiology, Osaka General Medical Centre, Osaka, Osaka, Japan (M Fukunami); Department of Cardiology, Kobe General Hospital, Kobe, Hyogo, Japan (A Yamamuro); Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Gifu, Japan (T Sone); Heart Centre Division of Cardiology, Social Insurance Kinan Hospital, Tanabe, Wakayama, Japan (Y Okumoto); Department of Circulatory Division, National Hospital Organisation Ureshino Medical Centre, Ureshino, Saga, Japan (S Hata); Department of Cardiovascular Medicine, Matsuyama Shimin Hospital, Matsuyama, Ehime, Japan (M Abe); Cardiovascular Centre, Anjo Kosei Hospital, Anjo, Aichi, Japan (Y Murata); Cardiovascular Division of Medicine, National Cardiovascular Centre, Suita, Osaka, Japan (S Yasuda); Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine, Saga, Saga, Japan (K Node); Department of Cardiology, Kawachi General Hospital, Higashiosaka, Osaka, Japan (M Mishima); Department of Cardiology, Engaru Kousei Hospital, Monbetsu-Gun, Hokkaido, Japan (H Honda); Department of Cardiology, Ehime Prefectural Imabari Hospital, Imabari, Ehime, Japan (H Matsuoka); Department of Cardiology, Tokushima Red Cross Hospital, Komatushima, Tokushima, Japan (Y Hiasa); Department of Cardiology, Musashino Red Cross Hospital, Musashino, Tokyo, Japan (T Miyamoto); Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Fukuoka, Japan (K Saku); Department of Cardiology, Chiba Emergency Medical Centre, Chiba, Chiba, Japan (I Ishibashi); Department of Cardiology, Saiseikai Fukuoka General Hospital, Fukuoka, Fukuoka, Japan (Y Yamamoto); Department of Cardiology, National Hospital Organisation Ibaraki-Higashi Hospital, Naka-Gun, Ibaraki, Japan (Y Eki); Department of Cardiology, Kawasaki Medical School Hospital, Kurashiki, Okayama, Japan (K Yoshida); Department of Cardiology,

Tokyo Metropolitan Bokutoh General Hospital, Sumida-Ku, Tokyo, Japan (I Kubo); Division of Cardiology, Omura Municipal Hospital, Omura, Nagasaki, Japan (Y Tanioka); Department of Cardiology, National Hospital Organisation Mito Medical Centre, Higashi Ibaraki-gun, Ibaraki, Japan (S Taguchi); Department of Cardiology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan (A Yamashina); Department of Cardiology, Fukuyama City Hospital, Fukuyama, Hiroshima, Japan (K Hashimoto); Department of Medicine, Nippon Medical School Chiba Hokuso Hospital, Inba-Gun, Chiba, Japan (K Mizuno); Department of Cardiology, Kanazawa Medical University, Kahoku-Gun, Ishikawa, Japan (S Okubo); Department of Internal Medicine, University of Yamanashi Faculty of Medicine, Chuo, Yamanashi, Japan (K Kugiyama); Department of Cardiology, Tsukazaki Memorial Hospital, Himeji, Hyogo, Japan (H Iida); Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan (I Komuro); Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kumamoto University, Kumamoto, Kumamoto, Japan (H Ogawa); Department of Cardiology, Shizuoka Prefectural General Hospital, Shizuoka, Shizuoka, Japan (O Doi); Division of Cardiology, Tokyo Metropolitan Geriatric Hospital, Itabashi-Ku, Tokyo, Japan (K Harada); Department of Internal Medicine, Cardiovascular Division, Asahikawa Medical College, Asahikawa, Hokkaido, Japan (N Hasebe); Department of Cardiology, Sasebo City General Hospital, Sasebo, Nagasaki, Japan (T Yamasa); Department of Internal Medicine, Division of Coronary Heart Disease, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan (M Masutani); Department of Cardiovascular Medicine, Graduate School of Medical Sciences Kyushu University, Fukuoka, Fukuoka, Japan (K Egashira); Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Bunkyo-Ku, Tokyo, Japan (M Isobe); Department of Internal Medicine and Cardiology, Graduate School of Medicine Osaka City University, Osaka, Osaka, Japan (M Yoshiyama); Department of Cardiology, Tokyo Women's Medical University, Shinjuku-Ku, Tokyo, Japan (H Kasanuki); Department of Cardiology, Nagasaki Citizens Hospital, Nagasaki, Nagasaki, Japan (S Suzuki); Department of Emergency and Critical Care Medicine, Chikushi Hospital Fukuoka University, Chikushino, Fukuoka, Japan (H Mihara).

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

These studies were supported by grants for Comprehensive Research on Ageing and Health (H13-21seiki (seikatsu) 23), in Health and Labour Sciences Research from Ministry of Health, Labour and Welfare, Japan, and by a grant from the Japanese Cardiovascular Research Foundation. We thank Satomi Ihara for her excellent assistance with data management; Hidetoshi Okazaki, Hiroyuki Yamamoto, Masakatsu Wakano, Atsushi Nakano, Hiroyuki Takahama, Shin Ito, Hideyuki Sasaki, and Kyungduk Min for analysis of angiographs of left ventricles; Yoshie Yanagi, Hiromi Ohara, Chikayo Tsujimoto, Naoko Matsuo, Yoshihiro Asano, Masashi Fujita, Shuichiro Higo, and Mitsutoshi Asai for data monitoring; Ms Uchida at SACT international for data analysis; Dr Tsutomu Yamazaki for data management; and Dr Ed Schweitzer for review of the manuscript.

References

- Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2006; 113: 85–151.
- Jessup M, Brozena S. Heart failure. *N Engl J Med* 2003; 348: 2007–18.
- Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. *N Engl J Med* 2002; 347: 1397–402.
- Shiba N, Watanabe J, Shinozaki T, et al. Poor prognosis of Japanese patients with chronic heart failure following myocardial infarction—comparison with nonischemic cardiomyopathy. *Circ J* 2005; 69: 143–49.
- Kloner RA, Rezkalla SH. Cardiac protection during acute myocardial infarction: where do we stand in 2004? *J Am Coll Cardiol* 2004; 44: 276–86.
- The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. *Eur Heart J* 1985; 6: 199–226.
- Ross AM, Gibbons RJ, Stone GW, Klopfer RA, Alexander RW. A randomised, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). *J Am Coll Cardiol* 2005; 45: 1775–80.
- van der Horst IC, Zijlstra F, van't Hof AW, et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomised trial. *J Am Coll Cardiol* 2003; 42: 784–91.
- Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1993; 328: 673–79.
- Sakurai K, Watanabe J, Iwabuchi K, et al. Comparison of the efficacy of reperfusion therapies for early mortality from acute myocardial infarction in Japan: registry of Miyagi Study Group for AMI (MsAMI). *Circ J* 2003; 67: 209–14.
- Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. *Circulation* 1995; 92: 1101–09.
- Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. *Circulation* 2002; 105: 2332–36.
- Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. *J Am Coll Cardiol* 2001; 38: 1644–50.
- European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. The ESPRIM trial: short-term treatment of acute myocardial infarction with molsidomine. *Lancet* 1994; 344: 91–97.
- Wall TC, Califf RM, Blankenship J, et al. Intravenous fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. *Circulation* 1994; 90: 114–20.
- Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. *J Clin Invest* 1986; 78: 1362–74.
- Emori T, Hirata Y, Imai T, Eguchi S, Kanno K, Marumo F. Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. *Endocrinology* 1993; 133: 2474–80.
- Kitakaze M, Minamino T, Node K, et al. Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of K⁺ channels. *Am J Physiol* 1996; 270: 1744–56.
- Mizumura T, Nithipatikom K, Gross GJ. Infarct size-reducing effect of nicorandil is mediated by the KATP channel but not by its nitrate-like properties in dogs. *Cardiovasc Res* 1996; 32: 274–85.
- Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. *J Am Coll Cardiol* 2001; 37: 1820–26.
- Kuga H, Ogawa K, Oida A, et al. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. *Circ J* 2003; 67: 443–48.
- Sugimoto K, Ito H, Iwakura K, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. *Circ J* 2003; 67: 295–300.
- Sakata Y, Kodama K, Komamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. *Am Heart J* 1997; 133: 616–21.
- Fukuzawa S, Ozawa S, Inagaki M, et al. Nicorandil affords cardioprotection in patients with acute myocardial infarction treated with primary percutaneous transluminal coronary angioplasty: assessment with thallium-201/iodine-123 BMIPP dual SPECT. *J Nucl Cardiol* 2000; 7: 447–53.

- 25 Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. *Circulation* 2005; 112: 1284–88.
- 26 Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, Kitakaze M. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by ANP (J-WIND-ANP). *Circ J* 2004; 68: 95–100.
- 27 Minamino T, Jiyoong K, Asakura M, Shintani Y, Asanuma H, Kitakaze M. Rationale and design of a large-scale trial using nicorandil as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of Necrotic Damage by a K-ATP channel opener (J-WIND-KATP). *Circ J* 2004; 68: 101–06.
- 28 Seino Y, Tomita Y, Hoshino K, Setsuta K, Takano T, Hayakawa H. Pathophysiological analysis of serum troponin T release kinetics in evolving ischemic myocardial injury. *Jpn Circ J* 1996; 60: 265–76.
- 29 Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. *J Am Coll Cardiol* 2006; 48: 2192–94.
- 30 Vollmer RT, Christenson RH, Reimer K, Ohman EM. Temporal creatine kinase curves in acute myocardial infarction. Implications of a good empiric fit with the log-normal function. *Am J Clin Pathol* 1993; 100: 293–98.
- 31 Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York, USA: Springer, 2000.
- 32 Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. *Stat Med* 1995; 14: 1707–23.
- 33 Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomised, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. *J Am Coll Cardiol* 1999; 34: 1711–20.
- 34 Grover GJ, Sleph PG, Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. *Circulation* 1992; 86: 1310–16.
- 35 IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. *Lancet* 2002; 359: 1269–75.

